References

  1. Chambers WA. Editorial. Ophthalmic generics – are they really the same? Ophthalmology. 2012;119(6):1095-6.
  2. Beers DO. Generic and innovator drugs: a guide to FDA approval requirements. 7th ed. Austin: Aspen Publishers;2008
  3. Noecker RJ, Simmons ST. The making of generic medicines. Glaucoma Today. 2010;Supplement Fall:6-7.
  4. Noecker RJ, Simmons ST. When a vehicle is not just a vehicle. Glaucoma Today. 2010; Supplement Fall:8-9.
  5. Dong JQ, Babusis DM, Welty DF, Acheampong AA, Tang-Liu D, Whitcup SM. Effects of the preservative Purite® on the bioavailability of brimonidine in the aqueous humor of rabbits. J Ocul Pharmacol Ther. 2004;20(4):285-92.
  6. Meseguer G, Buri P, Plazonnet B, Rozier A, Gurny R. Gamma scintigraphic comparison of eyedrops containing pilocarpine in healthy volunteers. J Ocul Pharmacol Ther. 1996;12(4):481-8.
  7. Dickstein K, Aarsland T. Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men. Am J Ophthalmol. 1996;121(4):367-71.
  8. Kahook MY, Fechtner RD, Katz LJ, Noecker RJ, Ammar DA. A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography-tandem mass spectrometry. Curr Eye Res. 2012;37(2):101-8.
  9. Mammo ZN, Flanagan JG, James DF, Trope GE. Generic versus brand-name North American topical glaucoma drops. Can J Ophthalmol. 2012;47(1):55-61.
  10. Flach A. Topically applied nonsteroidal anti-inflammatory drugs and corneal problems: an interim review and comment. Ophthalmology. 2000;107(7):1224-6.
  11. Congdon NG, Schein OD, von Kulajta P, Lubomski LH, Gilbert D, Katz J. Corneal complications associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs. J Cataract Refract Surg. 2001;27:622-31.
  12. Fiscella RG, Jensen M, Van Dyck G. Generic prednisolone suspension substitution. Arch Ophthalmol. 1998;116:703.
  13. Apt L, Henrick A, Silverman LM. Patient compliance with use of topical ophthalmic corticosteroid suspensions. Am J Ophthalmol. 1979;87(2):210-4.
  14. Roberts CW. A comparison of branded to generic prednisolone acetate for control of postoperative inflammation. Invest Ophthalmol Vis Sci. 2000;41:S150.
  15. Stewart WC, Sharpe ED, Stewart JA, Hott CE. The safety and efficacy of timolol 0.5% in xanthan gum versus timolol gel forming solution 0.5%. Curr Eye Res. 2002;24: 387-91.
  16. Narayanaswamy A, Neog A, Baskaran M, George R, Lingam V, Desai C, et al. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol. 2007;55(2):127-31.
  17. Strmen P, Jancus V, Okkelova J, Tvrdonova M. Clinical trial of the generic product UNILAT following its efficiency and safety in glaucoma and intraocular hypertension. Cesk Slov Oftalmol. 2010;66:258-61.
  18. Noecker RJ, Simmons ST. Generic ophthalmics and adverse events. Glaucoma Today. 2010;Supplement Fall:10-11.
  19. Noecker RJ, Simmons ST. Special challenges for glaucoma treatment. Glaucoma Today. 2010;Supplement Fall:13-15.
  20. Cantor LB. Ophthalmic generic drug approval process: implications for efficacy and safety. J Glaucoma. 1997;6(5):344-9
4th Edition - May 2017